The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > BUSINESS
BUSINESS
- Humira Remains Global Top-Seller in 2019
June 4, 2020
- Lilly Expects Topline Data for 2 COVID-19 Drug Candidates by June-End, First Patient Dosed in Antibody Treatment Study: Japan Execs
June 3, 2020
- Shionogi Aims at 500 Billion Yen Sales in FY2024: New 5-Year Plan
June 3, 2020
- Kyowa Hakko Bio’s GMP Breach Triggers Shipment Curbs, Stockouts at Astellas, Kowa; Impact Could Reverberate Further
June 3, 2020
- Asahi Kasei Pharma Grabs China Approval for Flivas
June 3, 2020
- Eisai’s Insomnia Med Dayvigo Now Available in US
June 3, 2020
- Fetroja Gets FDA’s Priority Review for Nosocomial Pneumonia
June 3, 2020
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
- Torii, ASKA to Copromote Riona for Iron Deficiency Anemia
June 2, 2020
- 15 Drug Makers See 3.6% Negative Growth in Japan in FY2020 as Re-Pricing, Generic Entries Weigh: Jiho Tally
June 2, 2020
- Onivyde Now Available in Japan: Servier/Yakult
June 2, 2020
- Daiichi Sankyo to Test TROP2-Directed ADC plus Keytruda in NSCLC
June 2, 2020
- Takeda Launching Project to Gauge Parkinson’s Symptoms with Wearables, Telemedicine Platform
June 2, 2020
- Takeda Gets CHMP Backing for Takhzyro Pre-Filled Syringe
June 2, 2020
- Teva Takeda to Curb Reminyl Generic Supply following June Listing due to India Lockdown
June 2, 2020
- 6 Japan Drug Makers Net 20% Growth in China Biz Despite COVID-19 Woes
June 1, 2020
- Sumitomo Dainippon to Merge Boston Biomedical, Tolero to Streamline Oncology R&D
June 1, 2020
- Top 4 Wholesalers See Higher Operating Profit Rates in FY2019 Driven by Anticancer Agents, Specialty Products
June 1, 2020
- Chugai Files Patent Litigation against Sawai, Nichi-Iko over Edirol Copies
June 1, 2020
- Takeda Winds Up Development of IBD Drug SHP647
June 1, 2020
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…